Last reviewed · How we verify
HS-20094
HS-20094 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival pathways.
HS-20094 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival pathways. Used for Oncology indication (specific indication not publicly disclosed).
At a glance
| Generic name | HS-20094 |
|---|---|
| Also known as | HS-20094 injection |
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact molecular target of HS-20094 has not been widely disclosed in public literature, it is being developed by Hansoh Pharmaceutical as an oncology agent in Phase 3 clinical trials. The compound likely functions through inhibition of a key signaling kinase to suppress tumor growth, though specific mechanistic details remain proprietary.
Approved indications
- Oncology indication (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US (PHASE2)
- A Phase 3 Study of HS-20094 in Patients With T2DM (PHASE3)
- A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone (PHASE3)
- A Study of HS-20094 in T2DM Participants (PHASE2)
- A Study of HS-20094 in Patients With T2DM (PHASE2)
- A Study of HS-20094 in Overweight or Obese Participants (PHASE1)
- A Study of HS-20094 in Chinese Adults with Overweight or Obesity (PHASE3)
- A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-20094 CI brief — competitive landscape report
- HS-20094 updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI